<html><body><h2>Case: 1571856</h2><h3> CDS Time: 1956-02-10</h3>
<patient name=1571856>
56.0 year old Asian_or_Pacific-Islander_Non-Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">56</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">132</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">3</td><td width="200">1954-3-11</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">64</td><td width="200">1955-9-24</td></tr>
<tr><td width="200">Chloride</td><td width="200">102.0</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">31</td><td width="200">1955-9-24</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">68</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Weight</td><td width="200">123</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">95</td><td width="200">1955-9-24</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">107</td><td width="200">1955-9-24</td></tr>
<tr><td width="200">SGOT</td><td width="200">56</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">106</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Height</td><td width="200">64</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">107</td><td width="200">1955-9-24</td></tr>
<tr><td width="200">BUN</td><td width="200">30</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">HCT</td><td width="200">50</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">HGB</td><td width="200">16</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">Sodium</td><td width="200">137</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">8</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">Pulse</td><td width="200">80</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">PLT</td><td width="200">128</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">WBC</td><td width="200">8</td><td width="200">1956-2-9</td></tr>
<tr><td width="200">SGPT</td><td width="200">75</td><td width="200">1956-2-5</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1956-1-28</td></tr>
<tr><td width="200">Angina</td><td width="200"></td><td width="200">1955-4-2</td></tr>
<tr><td width="200">Cardiomegaly</td><td width="200"></td><td width="200">1956-2-7</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1956-1-28</td></tr>
<tr><td width="200">Pacemaker</td><td width="200"></td><td width="200">1956-2-7</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1956-1-28</td></tr>
<tr><td width="200">Heart_Failure</td><td width="200"></td><td width="200">1956-1-28</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1956-1-28</td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">B 12</td><td width="200">>1000</td><td width="200">1954-4-12</td></tr>
</table>
<p><b>Medications:</b> triamterene(37.5) aspirin(81.0) spironolactone(25.0) losartan(25.0) metformin(1000.0) atorvastatin(80.0) digoxin(0.25) carvedilol(25.0) Insulin(0.04) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of angina]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(31.0/1955-9-24)]()</td></tr>
<tr><td width="200">Presence of K sparing diuretics</td>
<td width="200"></td>
<td width="200"> K sparing diuretics[presence of K sparing diuretics]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(106/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Heart Failure  (Secondary Prev) BP controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(106/null) && presence of heart failure]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(106/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Heart Failure (second prev) BP cont</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(106/null) && heart failure present]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.7/1956-2-9) && presence of MI]()</td></tr>
<tr><td width="200">Active prescription for ARB and aldosterone antagonist</td>
<td width="200"></td>
<td width="200"> Active prescription for ARB and aldosterone antagonist[Presence of ARB && presence of aldosterone antagonist]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">Hepatobiliary_Diseases</td>
<td width="200"></td>
<td width="200"> Active Liver Disease[SGOT(56.0/1956-2-5)]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1956-01-28</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1956-01-28</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">1956-02-07</td>
<td width="200"> Cardiomegaly()</td></tr>
<tr> <td width="200"></td>
<td width="200">1955-04-02</td>
<td width="200"> Angina()</td></tr>
<tr> <td width="200"></td>
<td width="200">1956-01-28</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.7/1956-2-9) && presence of MI]()</td></tr>
<tr><td width="200">Pacemaker</td>
<td width="200">1956-02-07</td>
<td width="200"> Pacemaker()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1956-01-28</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.7/1956-2-9) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1954-04-12</td>
<td width="200"> B 12()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(64.0/1955-9-24))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(68/null) && Treatment_Systolic_BP(106/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Class II a</b>
<ul>
<li>Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)
</ul>
<li><b>Class I</b>
<ul>
<li>Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
<li>Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
<li>Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).
</ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> because <i>Presence of HF</i>)])
Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)

Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])
Class I
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>hydralazine and nitrates<ul><li>preference: neutral<li>No comment</ul><li>aldosterone antagonist<ul><li>Already being used<li>preference: ruled out</ul><li>Beta blocker for stage C heart failure(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul><li>Beta blocker Stage C with MI(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul></ul><b>Considerations for adding drug: </b><ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font><li>Relative contraindications:  Active prescription for ARB and aldosterone antagonist(Active prescription for ARB and aldosterone antagonist[Presence of ARB && presence of aldosterone antagonist]) <li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)<li>monitoring renal function and K(Need to find content)<li>preference: preferred</ul><li>Beta Blocker Stage B no MI<ul><li>preference: neutral<li>No comment</ul><li>ARB<ul><li>Already being used<li>preference: ruled out</ul><li>digoxin<ul><li>Already being used<li>preference: ruled out</ul><li>Beta blocker stage B post MI(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul><li>NDHP CCB<ul><li>Contraindications:  Heart_Failure(Cardiomegaly, Heart_Failure)  Myocardial_Infarction(Myocardial_Infarction) <li>preference: ruled out</ul></ul></body></html>